St Jude Medical study shows benefits of migraine treatment
28 June 2011 00:00 in Medical Company Product News
St Jude Medical has published data from a new study showing the benefits of neuromodulation techniques for the treatment of chronic migraine.
The company has conducted a trial in which its Genesis neurostimulator was utilised to deliver peripheral stimulation of the occipital nerve to 157 participants suffering from headaches 26 days per month on average.
It was found that those receiving active treatment were able to experience benefits in terms of headache frequency and overall disability compared to the control group, with statistical significance achieved in accordance with most measures.
Dr Stephen Silberstein, the principal investigator of the study, said: "This research demonstrates that peripheral nerve stimulation can ease the suffering of chronic migraine patients."
St Jude Medical is currently seeking EU approval for Genesis as a treatment for migraines and hopes to launch the product in Europe in a limited capacity this year.
Last month, the company published research showing the cost-effectiveness benefits offered by fractional flow reserve technology, such as its PressureWire device, in treating heart disease.
Other news stories from 28/06/2011
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency